Yasodha Natkunam, M.D., Ph.D
Key Documents
Contact Information
-
Clinical Offices
Department of Pathology 300 Pasteur Dr L235 MC 5324 Stanford, CA 94305 Tel Work (650) 725-9354 Fax (650) 725-7409Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information EmailAlternate Contact Thelma Santa Maria Administrative Associate Email Tel Work 650-498-4987Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Hematopathology
- Pathology and Laboratory Medicine
- Anatomic/Clinical Pathology
Administrative Appointments
- Co-Director, Immunodiagnosis Laboratory, Stanford (2005 - present)
- Associate Chair for Hematopathology, Stanford (2009 - present)
- Associate Chair for Faculty Development and Diversity, Stanford (2009 - present)
Professional Education
| Residency: | SUMC - Graduate Medical Education CA (2000) |
| Board Certification: | Anatomic Pathology, American Board of Pathology (1998) |
| Internship: | Stanford University School of Medicine CA (1996) |
| Medical Education: | Mt. Sinai School of Medicine NY (1995) |
| PhD: | Mt.Sinai School of Medicine, Molecular Biology (1993) |
Graduate & Fellowship Program Affiliations
Community and International Work
Scientific Focus
Current Research Interests
My laboratory studies the tissue expression pattern of proteins that are of potential interest for the diagnosis, prognostic stratification and therapy of patients with lymphoma and leukemia. We are currently investigating prognostic markers in diffuse large B-cell lymphoma such that risk groups can be better defined. We are also interested in the immunodiagnostic and molecular characterization of rare and aggressive hematopoietic tumors such as Natural Killer/T-cell lymphomas, histiocytic malignancies and childhood lymphomas.
Clinical Trials
- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Recruiting
- Phase II study of Atorvastatin safety and antitumor effects in non-Hodgkin's Lymphoma Recruiting
- Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases Terminated
- Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer Completed
- Phase II Fludarabine, Cytoxan and FCCAM in Untreated B-Cell Chronic Lymphocytic Leukemia Completed
Publications
- Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma? Appl Immunohistochem Mol Morphol. 2012; (3): 325-30
- Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood. 2012
- IgG4-Related Systemic Sclerosing Disease of the Ocular Adnexa: A Potential Mimic of Ocular Lymphoma. Am J Clin Pathol. 2012; (5): 699-711
- LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leuk Lymphoma. 2012
- The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. Mod Pathol. 2012
